Sun Pharma Q2 profit drops 36% amid acquisition costs, revenue rises 12%
Just the facts

Sun Pharma Q2 profit drops 36% amid acquisition costs, revenue rises 12%

Summary

Sun Pharmaceutical Industries reported a 36.2% year-on-year decline in net profit for Q2 FY27, citing one-time acquisition and litigation settlement charges, while revenue grew 11.9%.

Sun Pharmaceutical Industries Ltd said its consolidated net profit fell 36.2% year-on-year to Rs 1,989 crore for the quarter ended September 2026, reflecting exceptional charges linked to the proposed Organon & Co acquisition and a settlement of a U.S. antitrust case. Revenue from operations rose 11.9% to Rs 16,198.7 crore, driven by growth in India and emerging-market businesses, even as U.S. formulation sales slipped.

Adjusted net profit improved slightly to Rs 3,162 crore, up 1.4% from the same period last year. EBITDA increased 4.8% to Rs 4,743.9 crore, giving a margin of 29.3%, while profit before exceptional items and tax rose 6.3% to Rs 4,428.2 crore.

India formulations sales reached Rs 5,552.3 crore, a 17.3% increase, representing 34.5% of total sales. U.S. formulations fell 8.2% to $455 million, accounting for about 27% of sales. Emerging-market formulations grew 7.6% to $350 million, and global innovative medicines rose 6.9% to $356 million.

"Our performance during the quarter was driven by strong momentum in India, Emerging Markets and Rest of World," said Kirti Ganorkar, Managing Director of Sun Pharma.

The company recorded Rs 346.16 crore in acquisition-related expenses for the Organon deal and disclosed a settlement of Rs 922.67 crore with a plaintiff in a U.S. generic-pricing antitrust litigation, including a tax benefit of Rs 95.34 crore. Product updates included U.S. approval for Ilumya in psoriatic arthritis, a preferred recommendation for Unloxcyt in advanced cutaneous squamous cell carcinoma, and licensing of the PCSK9 inhibitor lerodalcibep for markets outside the U.S. and China. R&D spending was Rs 778.4 crore, or 4.8% of sales.

Keep reading — for free

Create a free account to follow the news. No card required.